BIOMAT Database Logo BIOMAT Database Logo

Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists. 1998

D J Wustrow, and T Capiris, and R Rubin, and J A Knobelsdorf, and H Akunne, and M D Davis, and R MacKenzie, and T A Pugsley, and K T Zoski, and T G Heffner, and L D Wise
Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA.

A series of 3-phenylpyrazolo[1,5-a]pyrimidines was prepared and found to have affinity for the human CRF-1 receptor. The 3-dimensional structure of one of the most potent analogs in this series, 10d, was determined by X-ray crystallography and suggests the spatial requirements for potent CRF-1 receptor binding affinity in this series.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D003346 Corticotropin-Releasing Hormone A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. ACTH-Releasing Hormone,CRF-41,Corticotropin-Releasing Factor,Corticotropin-Releasing Hormone-41,ACTH-Releasing Factor,CRF (ACTH),Corticoliberin,Corticotropin-Releasing Factor-41,ACTH Releasing Factor,ACTH Releasing Hormone,Corticotropin Releasing Factor,Corticotropin Releasing Factor 41,Corticotropin Releasing Hormone,Corticotropin Releasing Hormone 41
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

D J Wustrow, and T Capiris, and R Rubin, and J A Knobelsdorf, and H Akunne, and M D Davis, and R MacKenzie, and T A Pugsley, and K T Zoski, and T G Heffner, and L D Wise
3-Aryl pyrazolo[4,3-d]pyrimidine derivatives: Nonpeptide CRF-1 antagonists.
August 2002, Bioorganic & medicinal chemistry letters,
D J Wustrow, and T Capiris, and R Rubin, and J A Knobelsdorf, and H Akunne, and M D Davis, and R MacKenzie, and T A Pugsley, and K T Zoski, and T G Heffner, and L D Wise
Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
October 2011, Bioorganic & medicinal chemistry,
D J Wustrow, and T Capiris, and R Rubin, and J A Knobelsdorf, and H Akunne, and M D Davis, and R MacKenzie, and T A Pugsley, and K T Zoski, and T G Heffner, and L D Wise
Pyrazolo-[1,5-a]-1,3,5-triazine corticotropin-releasing factor (CRF) receptor ligands.
September 2003, Bioorganic & medicinal chemistry,
D J Wustrow, and T Capiris, and R Rubin, and J A Knobelsdorf, and H Akunne, and M D Davis, and R MacKenzie, and T A Pugsley, and K T Zoski, and T G Heffner, and L D Wise
Pyrazolo[1,5-a]pyrimidine TRPC6 antagonists for the treatment of gastric cancer.
September 2018, Cancer letters,
D J Wustrow, and T Capiris, and R Rubin, and J A Knobelsdorf, and H Akunne, and M D Davis, and R MacKenzie, and T A Pugsley, and K T Zoski, and T G Heffner, and L D Wise
Structure of pyrazolo[1,5-a]pyrimidine methylderivatives.
January 1978, Il Farmaco; edizione scientifica,
D J Wustrow, and T Capiris, and R Rubin, and J A Knobelsdorf, and H Akunne, and M D Davis, and R MacKenzie, and T A Pugsley, and K T Zoski, and T G Heffner, and L D Wise
Synthesis and evaluation of novel pyrazolo[1,5-alpha]pyrimidine derivatives as nonpeptide angiotensin II receptor antagonists.
June 1995, Chemical & pharmaceutical bulletin,
D J Wustrow, and T Capiris, and R Rubin, and J A Knobelsdorf, and H Akunne, and M D Davis, and R MacKenzie, and T A Pugsley, and K T Zoski, and T G Heffner, and L D Wise
Synthesis and structure-activity relationship of a new series of potent angiotensin II receptor antagonists: pyrazolo[1,5-a]pyrimidine derivatives.
July 1999, Chemical & pharmaceutical bulletin,
D J Wustrow, and T Capiris, and R Rubin, and J A Knobelsdorf, and H Akunne, and M D Davis, and R MacKenzie, and T A Pugsley, and K T Zoski, and T G Heffner, and L D Wise
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists.
November 1999, Journal of medicinal chemistry,
D J Wustrow, and T Capiris, and R Rubin, and J A Knobelsdorf, and H Akunne, and M D Davis, and R MacKenzie, and T A Pugsley, and K T Zoski, and T G Heffner, and L D Wise
Pyrazolo[1,5-a]pyrimidine-based inhibitors of HCV polymerase.
November 2009, Bioorganic & medicinal chemistry letters,
D J Wustrow, and T Capiris, and R Rubin, and J A Knobelsdorf, and H Akunne, and M D Davis, and R MacKenzie, and T A Pugsley, and K T Zoski, and T G Heffner, and L D Wise
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
March 1996, Journal of medicinal chemistry,
Copied contents to your clipboard!